S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:CERS

Cerus Stock Forecast, Price & News

$5.76
-0.44 (-7.10 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.71
Now: $5.76
$6.28
50-Day Range
$5.90
MA: $7.11
$7.87
52-Week Range
$2.71
Now: $5.76
$8.87
Volume3.15 million shs
Average Volume2.19 million shs
Market Capitalization$968.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Cerus logo

Headlines

Cerus: 4Q Earnings Snapshot
February 26, 2021 |  finance.yahoo.com
Cerus Corporation (CERS) Q4 2020 Earnings Call Transcript
February 26, 2021 |  finance.yahoo.com
Cerus (CERS) Reports In-Line Q4 EPS - StreetInsider.com
February 26, 2021 |  streetinsider.com
Cerus EPS in-line, beats on revenue - Seeking Alpha
February 25, 2021 |  seekingalpha.com
Cerus Corp. to Host Earnings Call
February 25, 2021 |  finance.yahoo.com
A Preview Of Cerus's Earnings - Benzinga
February 24, 2021 |  benzinga.com
A Preview Of Cerus's Earnings
February 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:CERS
CUSIP15708510
Phone(925) 288-6000
Employees254
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.65 million
Book Value$0.41 per share

Profitability

Net Income$-71,240,000.00

Miscellaneous

Market Cap$968.95 million
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

199th out of 1,971 stocks

Surgical & Medical Instruments Industry

21st out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$5.76
-0.44 (-7.10 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cerus (NASDAQ:CERS) Frequently Asked Questions

Is Cerus a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cerus stock.
View analyst ratings for Cerus
or view top-rated stocks.

What stocks does MarketBeat like better than Cerus?

Wall Street analysts have given Cerus a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cerus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Cerus
.

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings data on Thursday, February, 25th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01. Cerus had a negative trailing twelve-month return on equity of 63.47% and a negative net margin of 73.72%.
View Cerus' earnings history
.

How has Cerus' stock price been impacted by Coronavirus?

Cerus' stock was trading at $4.76 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CERS shares have increased by 21.0% and is now trading at $5.76.
View which stocks have been most impacted by COVID-19
.

What guidance has Cerus issued on next quarter's earnings?

Cerus issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $106-110 million, compared to the consensus revenue estimate of $131.2 million.

What price target have analysts set for CERS?

3 brokerages have issued 1-year target prices for Cerus' shares. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' stock price to reach $7.83 in the next twelve months. This suggests a possible upside of 36.0% from the stock's current price.
View analysts' price targets for Cerus
or view top-rated stocks among Wall Street analysts.

Who are Cerus' key executives?

Cerus' management team includes the following people:
  • Obi Greenman, President, Chief Executive Officer & Director
  • Vivek K. Jayaraman, Chief Operating Officer
  • Kevin Dennis Green, Chief Financial Officer & Vice President-Finance
  • Laurence M. Corash, Chief Scientific Officer
  • Carol M. Moore, Senior VP-Regulatory Affairs, Quality & Clinical

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus CEO William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among Cerus' employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.41%), Sumitomo Mitsui Trust Holdings Inc. (6.64%), Nikko Asset Management Americas Inc. (6.64%), Primecap Management Co. CA (6.24%), Hood River Capital Management LLC (1.34%) and Northern Trust Corp (1.26%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends for Cerus
.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Kennedy Capital Management Inc., Primecap Management Co. CA, Peregrine Capital Management LLC, Northern Trust Corp, First Midwest Bank Trust Division, Salzhauer Michael, and Mackenzie Financial Corp. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Vivek K Jayaraman, and William Mariner Greenman.
View insider buying and selling activity for Cerus
or view top insider-selling stocks.

Which institutional investors are buying Cerus stock?

CERS stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Norges Bank, Bamco Inc. NY, Morgan Stanley, Renaissance Technologies LLC, Senvest Management LLC, and Sepio Capital LP. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus
or or view top insider-buying stocks.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $5.76.

How much money does Cerus make?

Cerus has a market capitalization of $968.95 million and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Cerus have?

Cerus employs 254 workers across the globe.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

Where are Cerus' headquarters?

Cerus is headquartered at 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at (925) 288-6000 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.